Fibrosis/Cirrhosis
Fibrosis & Cirrhosis
AASLD 2015: Coffee Linked to Reduced Liver Fibrosis in People with HBV, HCV, and NAFLD
- Details
- Category: Fibrosis & Cirrhosis
- Published on Wednesday, 25 November 2015 00:00
- Written by Liz Highleyman
Drinking coffee was associated with lower liver stiffness -- a non-invasive measure used to estimate liver fibrosis -- in people with hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD), researchers reported at the 2015 AASLD Liver Meeting last week in San Francisco. The study also showed a trend toward less liver fat build-up in people with NAFLD.
Can Coffee Help Prevent Liver Fibrosis?
- Details
- Category: Fibrosis & Cirrhosis
- Published on Friday, 07 February 2014 00:00
- Written by Liz Highleyman
There is good evidence that coffee has a beneficial effect in people at risk for liver fibrosis and there are plausible biological mechanisms to explain why, according to an editorial in the January 27 advance online edition of Hepatology. However, the amount needed to see such an effect may be too high for many people to tolerate, they cautioned.
Antiviral Therapy Safe and Effective for Hep B Patients with Advanced Cirrhosis
- Details
- Category: HBV Treatment
- Published on Tuesday, 06 November 2012 00:00
- Written by Liz Highleyman
Antiviral drugs including entecavir (Baraclude), lamivudine (Epivir-HBV), telbivudine (Tyzeka), and tenofovir (Viread) are generally well-tolerated and effective against hepatitis B virus (HBV) in people with liver cirrhosis, and may lower mortality even among patients with severe decompensated cirrhosis, according to 2 recently published studies.
Most Hepatitis B Patients Who Respond to Tenofovir Show Improved Liver Health at 5 Years
- Details
- Category: HBV Treatment
- Published on Thursday, 27 December 2012 00:00
- Written by Liz Highleyman
Treatment with tenofovir (Viread) remains safe and effective over 5 years, and people who achieve sustained viral load suppression experience improvement in liver histology, including regression of fibrosis and cirrhosis, according to study findings described in the December 7, 2012, advance online edition of The Lancet.
AASLD 2011: Long-Term Tenofovir for Chronic Hepatitis B Reduces Liver Inflammation and Cirrhosis
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 November 2011 00:00
- Written by Gilead Sciences
Most chronic hepatitis B patients who maintain viral suppression on tenofovir (Viread) for 5 years experience improvement in liver histology, including regression of cirrhosis, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.
More Articles...
- Entecavir vs Adefovir in Hepatitis B Patients with Liver Decompensation
- Long-term Entecavir Leads to Regression of Liver Fibrosis in Chronic Hepatitis B Patients
- Sex Hormone Receptor May Explain Higher Risk of Hepatocellular Carcinoma in Men
- Appetite-regulating Hormone Ghrelin May Inhibit Inflammation and Liver Fibrosis
Web Design and Development by